CD274 and cancer: The activation of T-cells and cell-mediated immune responses against the tumor are enhanced by blocking the activation of PD-1 by its ligands programmed cell death ligand 1 (PD-L1)—overexpressed on certain cancer cells—and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells.